BioCentury | Mar 10, 2021
Product Development

Following fast-fail model, Quench passes on hard-to-drug inflammation target gasdermin D

...at Synlogic Inc. (NASDAQ:SYBX) and CBO of Padlock Therapeutics Inc....
BioCentury | Nov 17, 2020
Management Tracks

Gujrathi leaving as Gossamer CEO; plus Spark, Atlas, Flagship, Talaris

...Lilly and Co. (NYSE:LLY) for $135 million up front and $1.2 billion in milestones; and Padlock Therapeutics Inc....
BioCentury | Apr 8, 2020
Deals

RNA-targeting small molecule play Arrakis taps Roche as first pharma partner

...founding CEO of Stromedix Inc., which Bristol Myers Squibb Co. (NYSE:BMY) acquired in 2012; and Padlock Therapeutics Inc....
BioCentury | Jan 28, 2020
Company News

Quenching the flames of inflammatory cell death

...was previously COO and head of corporate development at Synlogic Inc. (NASDAQ:SYBX) and CBO of Padlock Therapeutics Inc....
BioCentury | Oct 30, 2018
Company News

Management tracks: Blueprint, Clovis

...positions include COO and head of corporate development of Synlogic Inc. (NASDAQ:SYBX) and CBO of Padlock Therapeutics Inc....
BioCentury | Aug 28, 2018
Preclinical News

Stealth start-up Quench among teams tying protein to inflammatory cell death

...Truex was COO and head of corporate development at Synlogic Inc. (NASDAQ:SYBX) and CBO of Padlock Therapeutics Inc....
BioCentury | Mar 9, 2017
Finance

Pharmas learn their A, B, seeds

...options, deals or specific rights to our investments.” Notable platform investments by the fund include Padlock Therapeutics Inc....
BioCentury | Mar 2, 2017
Product R&D

RNA, meet small molecules

...to developing therapeutics against RNA employ antisense oligos or RNAi. However Gilman, who previously founded Padlock Therapeutics Inc....
BioCentury | Feb 28, 2017
Financial News

Arrakis raises $38M to pursue RNA platform

...one-time EVP of research at Biogen Inc. (NASDAQ:BIIB), most recently was CEO of autoimmune play Padlock Therapeutics Inc....
BioCentury | Dec 23, 2016
Company News

Management tracks

...Cambridge, Mass.) named Samantha Truex COO and head of corporate development. She was CBO at Padlock Therapeutics Inc....
Items per page:
1 - 10 of 32
BioCentury | Mar 10, 2021
Product Development

Following fast-fail model, Quench passes on hard-to-drug inflammation target gasdermin D

...at Synlogic Inc. (NASDAQ:SYBX) and CBO of Padlock Therapeutics Inc....
BioCentury | Nov 17, 2020
Management Tracks

Gujrathi leaving as Gossamer CEO; plus Spark, Atlas, Flagship, Talaris

...Lilly and Co. (NYSE:LLY) for $135 million up front and $1.2 billion in milestones; and Padlock Therapeutics Inc....
BioCentury | Apr 8, 2020
Deals

RNA-targeting small molecule play Arrakis taps Roche as first pharma partner

...founding CEO of Stromedix Inc., which Bristol Myers Squibb Co. (NYSE:BMY) acquired in 2012; and Padlock Therapeutics Inc....
BioCentury | Jan 28, 2020
Company News

Quenching the flames of inflammatory cell death

...was previously COO and head of corporate development at Synlogic Inc. (NASDAQ:SYBX) and CBO of Padlock Therapeutics Inc....
BioCentury | Oct 30, 2018
Company News

Management tracks: Blueprint, Clovis

...positions include COO and head of corporate development of Synlogic Inc. (NASDAQ:SYBX) and CBO of Padlock Therapeutics Inc....
BioCentury | Aug 28, 2018
Preclinical News

Stealth start-up Quench among teams tying protein to inflammatory cell death

...Truex was COO and head of corporate development at Synlogic Inc. (NASDAQ:SYBX) and CBO of Padlock Therapeutics Inc....
BioCentury | Mar 9, 2017
Finance

Pharmas learn their A, B, seeds

...options, deals or specific rights to our investments.” Notable platform investments by the fund include Padlock Therapeutics Inc....
BioCentury | Mar 2, 2017
Product R&D

RNA, meet small molecules

...to developing therapeutics against RNA employ antisense oligos or RNAi. However Gilman, who previously founded Padlock Therapeutics Inc....
BioCentury | Feb 28, 2017
Financial News

Arrakis raises $38M to pursue RNA platform

...one-time EVP of research at Biogen Inc. (NASDAQ:BIIB), most recently was CEO of autoimmune play Padlock Therapeutics Inc....
BioCentury | Dec 23, 2016
Company News

Management tracks

...Cambridge, Mass.) named Samantha Truex COO and head of corporate development. She was CBO at Padlock Therapeutics Inc....
Items per page:
1 - 10 of 32